AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05623735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization Group While Lying Prone
Description: 1. Sliding movements in all directions at 30 - 60 degree angles will be made in the form of mobilizations of 45 seconds with instruments.~2. Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~3. Starting with an angle of 60 degrees on the area to be treated, the movement of shifting towards an angle of 30 degrees will be made in all directions for 30 seconds.~4. The tissue will be mobilized for 30 consecutive seconds, starting from just caudal to your waist and drawing the letter J towards the cranial.~5. Sliding movements in all directions at 30 - 60 degree angles will be made with instruments in the form of mobilizations for 45 seconds.~6. Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~7. 30 - 60 degree swipe movement shorter brushing style small movements will be done for 30 seconds.
Study NCT05623735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization Group Combined with Functional Movement
Description: 1. Sliding movements in all directions at 30 - 60 degree angles will be made in the form of mobilizations of 45 seconds with instruments.~2. Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~3. Starting with an angle of 60 degrees on the area to be treated, the movement of shifting towards an angle of 30 degrees will be made in all directions for 30 seconds.~4. The tissue will be mobilized for 30 consecutive seconds, starting from just caudal to your waist and drawing the letter J towards the cranial.~5. Sliding movements in all directions at 30 - 60 degree angles will be made with instruments in the form of mobilizations for 45 seconds.~6. Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~7. 30 - 60 degree swipe movement shorter brushing style small movements will be done for 30 seconds.
Study NCT06219343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive vagus nerve stimulation
Description: Patient undergoes non-invasive vagus nerve stimulation during tachycardia episodes to see if reentry is possible
Study NCT06527079 — intervention group
Intervention type: OTHER
Intervention: Opioid Tapering Pathway Clinical Decision Support (CDS)
Description: Clinical decision support in the form of an electronic health record (EHR)-integrated, provider facing notification suggesting the provider utilize a clinical care pathway that provides resources and decision support in opioid tapering in line with CDC guidelines.
Study NCT05085288 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent electrical stimulation system (IES) treatment and turning patient every two hours
Description: The investigators propose to assess whether addition of the IES system and the use of standard of care wound care and wound prevention reduces the morbidity of sacral and ischial pressure injuries by decreasing progression of stage 1 and stage 2 ulcers or facilitates their healing compared to standard wound care in an inpatient critical care population.
Study NCT05085288 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Turning population every two hours
Description: The investigators propose to assess whether current standard of care wound care and wound prevention reduces the morbidity of sacral and ischial pressure injuries.
Study NCT06034197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGT-309
Description: 0.32mg/kg IV of VGT-309 given 12-36 hours before surgery
Study NCT06510491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Bispecific antibody, via subcutaneous (under the skin) injection per protocol.
Study NCT04772131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Desara® One Single Incision Sling
Description: Single incision sling
Study NCT04772131 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Desara® Blue Transobturator Sling
Description: Standard mid-urethral sling
Study NCT05708378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rocker board training
Description: Patients will perform 24 sessions (4 times per week over 6 weeks) and effects will be measured before treatment, at 3rd and after 6th week.
Study NCT05708378 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stable surface training
Description: Patients will perform 24 sessions (4 times per week over 6 weeks) and effects will be measured before treatment, at 3rd and after 6th week.
Study NCT05652179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: After the induction of general anesthesia and before the start of the surgery,ultrasound-guided stellate ganglion block is performed, injecting 5 ml of 0.375% ropivacaine.
Study NCT04887298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Annamycin (L-Annamycin)
Description: 2-hour intravenous (IV) infusion of L-Annamycin on Day 1 followed by 20 days off of study drug (i.e., 1 treatment cycle= 21 days)
Study NCT06346522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin (Gaptin ®) 400mg oral capsule once
Description: After the patient will regain feeding, the patients will take with sips of water Gabapentin (Gaptin ®) 400mg oral capsule once in the first 24 hour after icu admission
Study NCT06346522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trospium chloride slow release (Trospikan ® SR) 60mg oral capsule
Description: After the patient will regain feeding, the patients will take with sips of water Trospium chloride slow release (Trospikan ® SR) 60mg oral capsule once in the first 24 hour after icu admission
Study NCT05299892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Audeo P or Naida P hearing aid
Description: Commercially available hearing aid that has access to speech enhancer feature settings off, moderate and strong
Study NCT05274438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001+Imatinib mesylate
Description: This study consisted of two phases: the first phase was the dose exploration phase, and the second phase was the extension group. In phase I, 3 patients were enrolled, starting with imatinib monotherapy, 400mg qd, for 2 cycles (6 weeks), followed by imatinib 400mg qd combined with toripalimab 240mg q3w. If DLT was not observed, the original dose was extended to 37 patients in phase ii; If there was 1 DLT in the first stage, the number of patients in the first stage was extended to 6. If there was no DLT, the patients entered the extended stage. If ≥2 DLT cases occurred in the first phase, imatinib was reduced to 300mg QD and toripalimab 240mg q3W, and the 3+3 study was restarted. If DLT≤1 case, enter extended group (imatinib 300mg qd and toripalimab 240mg q3W); The longest cumulative use period of the two drugs was 2 years. When patients develop disease progression or develop intolerable toxicity, treatment is ended and follow-up for survival is entered.
Study NCT06204315 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Given by RTx
Study NCT05900245 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Index of consciousness+Anesthetic（propofol）+Muscle relaxant（Succinylcholine）
Description: EEG monitoring is performed before induction of electrical shock anesthesia（propofol1.5mg/kg+Succinylcholine1mg/kg）, and the timing of electrical stimulation is determined based on the level of consciousness index 1 displayed on the EEG.
Study NCT06398314 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Palliative radiotherapy
Description: Hypofractionated radiotherapy
Study NCT05324371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Watchman FLX Device
Description: Left atrial appendage closure using the Watchman FLX device
Study NCT05947071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard Dose Quadrivalent Inactivated Influenza Vaccine
Description: Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
Study NCT05947071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose Quadrivalent Inactivated Influenza Vaccine
Description: Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration.
Study NCT05195138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Diabetes Education
Description: Mindfulness-Based Diabetes Education described in study arm.
Study NCT05195138 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Diabetes Self-Management Education (DSME)
Description: Standard DSME described in study arm.
Study NCT05991232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Ketamine
Description: Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
Study NCT05740904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New defocus spectacle lenses
Description: The children in the new defocus spectacle lens group will wear new defocus spectacle and receive follow-up examinations every half year.
Study NCT05740904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Convenional aspheric single-vision spectacle lenses
Description: The children in the convenional aspheric spectacle lenses group will wear conventional aspheric single-vision spectacle and receive follow-up examinations every half year.
Study NCT05030298 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT05030298 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Description: Undergo radiosurgery
Study NCT05030298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Biopsy
Description: Undergo MRI-guided stereotactic biopsy
Study NCT05030298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Drug
Study NCT05030298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields Therapy
Description: Undergo TTF
Study NCT05030298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05030298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05030298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05030298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT06157905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Tofacitinib citrate
Description: oral tofacitinib citrate was initiated at 5 mg twice daily after ruling out contraindications
Study NCT05163847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cam2020 M2SR H3N2 influenza vaccine
Description: Administered intranasally on Day 1
Study NCT05163847 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone HD IIV
Description: Administered intramuscularly on Day 1
Study NCT05163847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone HD IIV
Description: Administered intramuscularly on Day 1
Study NCT05163847 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IN Placebo
Description: Administered intranasally on Day 1
Study NCT05163847 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IN Placebo
Description: Administered intranasally on Day 1
Study NCT05842798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNM002
Description: TNM002, intramuscular injection
Study NCT05163847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IM Placebo
Description: Administered intramuscularly on Day 1
Study NCT05163847 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IM Placebo
Description: Administered intramuscularly on Day 1
Study NCT05570487 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Since the data were collected retrospectively, there were no interventions
Description: Since the data were collected retrospectively, there were no interventions
Study NCT03991273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Y-M2M©
Description: The Y-M2M© group will receive classes that will be delivered onsite at a YMCA facility. Movement-to-Music (M2M©) is an instructor-guided exercise program that is coupled with music to enhance strength, cardiorespiratory capacity, range of motion, and balance.
Study NCT03991273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B-M2M©
Description: The B-M2M© group will receive the same onsite M2M© classes as the Y-M2M© group, but they will also be provided with the option of performing home-based M2M© that will be delivered via videoconferencing.
Study NCT06449053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ORGANIZATIONAL
Description: A. a formalization of the recommendations to be applied to prevent DILH B. implemented and facilitated by an e-health application C. and will be based on adapting the hospital environment (connected mats, movement sensors, prescription assistance) D. and the dissemination of knowledge (production of summary and empowerment documents).
Study NCT06456073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E-CEL UVEC cells (AB-207)
Description: Allogeneic (consented-maternal donor) E4ORF1+ (pro-survival gene transduced) human umbilical vein endothelial cells (percutaneous injection formulation)
Study NCT05111223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real transcranial magnetic stimulation (TMS) before conditioning
Description: Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the conditioning phase of the task.
Study NCT05842798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, intramuscular injection
Study NCT05111223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real transcranial magnetic stimulation (TMS) before devaluation test
Description: Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the devaluation test phase of the task.
Study NCT05111223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham transcranial magnetic stimulation (TMS)
Description: Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.
Study NCT06239350 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Counseling
Description: Research staff will provide skills-based counseling at remote weekly visits, starting at Day 0. Counseling sessions will be brief (\~5-10 minutes) and will focus on strategies for preparing for the quit attempt, dealing with triggers, refusal skills, and enhancing motivation.
Study NCT06239350 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Contingency management
Description: Contingency management (CM): CM will be provided to all study participants to promote abstinence from all nicotine products. Incentives for abstinence (based on submission of a negative cotinine sample) will be provided on an escalating schedule during treatment (Days 8-84).
Study NCT06239350 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Text-based support
Description: All participants will be provided with evidence-based nicotine cessation resources. For those who are vaping nicotine, participants will be provided information for This is Quitting (SMS text-based program). For those who are primarily smoking cigarettes, NCI's QuitSTART (mobile app, web content), as well SmokefreeTXT (SMS-text based program), will be recommended, potentially in addition to This is Quitting for those using multiple products. These resources provide real time monitoring of nicotine use, mood, triggers and lapses.
Study NCT06560294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized purified flavonoid fraction (Daflon ®)
Description: Patients will receive micronized purified flavonoid fraction (Daflon ®), 500 mg twice/daily for 3 months.
Study NCT06380998 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: whey protien
Description: Whey, the supernatant of yogurt and a byproduct of cheese, is rich in protein and consists of β-lactalbumin, α-lactoglobulin, immunogloblin, bovine serum albumin, and other minor proteins. Whey protein is a globally consumed food material and is well known for its health benefits
Study NCT06560294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glue embolization
Description: Patients will receive transcatheter glue embolization.
Study NCT06043037 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elamrousy Novel Approach for Immediate Implant Placement Using Socket Shield Technique
Description: The flapless strategy was used. To prepare the SS, tooth decoronation followed by root splitting mesio-distally. The palatally splitted portion of the root is atraumatically extracted while the intact buccal root portion is kept in place with thickness of 1.5mm.(12) The implant fixture is then placed palatally with 2mm gap distance in between. finally, that gap was grafted with ADDG
Study NCT06043037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate Implant Placement Using Socket Shield Technique alone
Description: The flapless strategy was used. To prepare the SS, tooth decoronation followed by root splitting mesio-distally. The palatally splitted portion of the root is atraumatically extracted while the intact buccal root portion is kept in place with thickness of 1.5mm.(12) The implant fixture is then placed palatally with 2mm gap distance in between. finally, that gap was left without grafts.
Study NCT05422079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-specific lumbar exercise group
Description: Subjects perform a conventional lumbar exercise program twice a week.
Study NCT05422079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor control lumbar exercises
Description: Subjects perform a lumbar stabilization exercise program.
Study NCT05422079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor control lumbar exercises with ultrasound echography feedack
Description: Subjects perform a lumbar stabilization exercise program in conjunction with a video where participants can see how the muscles contract.
Study NCT05014178 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sodium-23 MRI
Description: Participants will lay in the MRI bed for approximately 60 minutes during scanning while the MRI technologist takes detailed pictures of their kidneys.
Study NCT05671965 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xylitol
Description: 33.5g xylitol dissolved in 300mL tap water.
Study NCT05671965 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: 33.5g sucrose dissolved in 300mL tap water.
Study NCT05671965 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Acesulfame Potassium
Description: 0.1675g Ace-K dissolved in 300mL tap water.
Study NCT05483127 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A toric soft contact lenses
Description: Soft contact lenses for optical correction of ametropia and astigmatism
Study NCT05483127 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Stenfilcon A toric soft contact lenses
Description: Soft contact lenses for optical correction of ametropia and astigmatism
Study NCT05671965 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 300mL tap water.
Study NCT06346483 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dusting without Moses 2.0 Modulation
Description: Dusting is when a laser is used to break a stone down into tiny fragments that are able to pass through the urine.
Study NCT06346483 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dusting with Moses 2.0 Modulation
Description: Dusting is when a laser is used to break a stone down into tiny fragments that are able to pass through the urine.
Study NCT06346483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moses 2.0 Modulation
Description: Lumenis Pulse™ 120H Holmium Laser System with MOSES™ 2.0 Technology used for lithotripsy and BPH treatments
Study NCT06007690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bel-sar
Description: Bel-sar via suprachoroidal administration followed by laser application.
Study NCT06007690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suprachoroidal Microinjector
Description: Suprachoroidal injection device
Study NCT06007690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrared Laser
Description: Laser application